contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


transactions-in-zealand-pharma-shares-andor-related-securities-by-persons-discharging-managerial-responsibilities-andor-their-closely-associated-persons-49

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Zealand Pharma

Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons...

Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&amp;D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at <a href="https://www.globenewswire.com/Tracker?data=9LQ84PPjtCQRJ3ezXOA2PdA5vPTS0fUTWOOPMJVY-nmkaiLdqGs8CbOwVU5DJ6xrzqJ6k-CAX6AQiOEkrkGS8LjUrmJRbF6T9ICcwttiK2g=">www.zealandpharma.com</a>. Contact Adam Lange (Investors) Vice President, Investor Relations Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=E-AXs8CizxtxczOXahO1EGKLRz0RV2Jr7elxn4xRoW_xmTFVzu7Hx11e1tWnar3YPck5CShuFGB50ouHoWCFjXMoqy10geE5OvOfb7-a6Mu8V2CLJJ6Q4fIiz4pR_t0M">alange@zealandpharma.com</a> Neshat Ahmadi (Investors) Investor Relations Manager Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=CTP2P4J_162mVJAqHaeLd2V_O6uoE-uGSNwqzjfhTYC3rooAppkqHF3qogpYJ9WWITrOuPeg5oyjOUo6STn6QSWD2h6VTQE24uFZx3p3hf7PFnqGr8pYG3jTNysn7fmd">neahmadi@zealandpharma.com</a> Rachel James-Owens (Media) Vice President, Corporate Communications &amp; Media Relations Zealand Pharma <a href="https://www.globenewswire.com/Tracker?data=dx4XJkG03G2iVEEZiJ4wVYYgZqvU1rfkMvH-0tcPtxkPPE4m7-Y9pnRH8TsNqSKJIQzfbmcLi39d9U34ARYhVy2-4vz_8u_kcqfBnvSFjCC-t5NuzZ_0wZqiXhXMwKQN25M3VQtj48HpIJ6CMUhjzQG8f8pVBakYJgaQ7lotvAwZOtPKSc6Il0uo2PH_cl-0Ba32lPFcTg6NMDhEsARMKURSu6IOQ29-jhqvYUWcjH_rIbEqMtGcjTocQVJQdrUvc_CTnsxFYfy8yMD_N1-MaO1tHVGvNL6JQdEaGNonRGbH0T3zu3c-tPEoJ4RBTSMaPtz4awbi9HkzzIPvngEiVykI4Oo7t8U_jj8jXaQJDactxo-6BXv-eXCtah8qLVqrpeGO2JtrEijZy5AoWTMXZc73xlTARI8BYiqqUTBpHiNbJ8ynxOB6pHVmh0URA00ALNvSvmyqqDKDkmNQJusFO0taoZR2HGPcffDY5D88G3zrbryVfwxDlOm_-JmNXRzzOqMGekfGS60THProGtAliPTCQbEFv0ymuEnVMmvmj8PUE6UBkIXXkDjtebt6OsIi">RJamesOwens@zealandpharma.com</a> Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/9779a267-edfa-43b0-927c-bd5d9f2d0c1f">2025-12-19_PDMR notifications</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0NTk0OSM0MDIyODYyMzEjMjAwMTcwMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/NzJlZGM2MmMtZWFjMi00MDE2LTk4MzItNDQyYTU2OWMzODIxLTEwMTMyNzQtMjAyNS0xMi0xOS1lbg==/tiny/Zealand-Pharma.png" alt="">

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons